The information of this article is obsolete. Please check FDA website for information.
AMN 107 AMN107, an investigational drug, is producing powerful responses in patients diagnosed with chronic myeloid leukemia, resistant to Gleevec. Novartis is the manfacturers for both AMN107 and Gleeve. Increasing Benefit Seen in Novel Drug That Treats Gleevec Resistance, Newswise, April 13, 2005. Source University of Texas M.D. Anderson Cancer Center.
AVASTIN (BEVACIZUMAB) Colorectal cancer is the third most common cancer. Approximately 147,500 new cases were diagnosed in 2003. AVASTIN is the first line treatment for patients with metastatic colorectal cancer.
The interim results of a late-stage trial showed that Avastin was successful when used with chemotherapy in untreated breast cancer which has spread to other parts of the body. About 8-9% of women will develop breast cancer during their lifetime. Roche's Avastin Works in Third Type of Cancer, Reuters, April 15, 2005
Avastin has achieved sales of $469 million in the first half of 2005. Pfizer seeks approval for cancer drug Reuters Aug 10 2005.
THALIDOMIDE Multiple myeloma affects about 50,000 American. About 14,600 new cases occur annually. Celgene's thalidomide was found to be effective for treating patients with multiple myeloma, a form of blood cancer in a phase III trial.Celgene Says Blood Cancer Patients Respond to Drug, Reuters, June 7, 2004.
ERBITUX About 40,000 Americans are diagnosed each year with oral, head and neck cancers. Radiation is a standard treatment. Tumors were less likely to spread in patients who took ImClone Systems' Erbitux in combination with radiation. Erbitux works by blocking a protein called epidermal growth factor which helps tumor cells reproduce. Erbitux Prolongs Survival in Head and Neck Cancer, Ransdell Pierson, Reuters, June 5, 2004.
PROXINIUM Viventia initates a second Phase I clinical trial for treatment of head and neck cancer with Proxinium. Press Release, June 7, 2004
TAXOTERE 230,900 new cases of prostate cancer may occur this year in the United States. It was found that men with aggressive prostate cancer treated with Aventis' Taxotere lived longer than patients treated with other standard chemotherapy drugs in Phase III trials. Related News Aventis Drug Prevails in Prostate Cancer Trials, by Pierson et al, Reuters, Jun 7, 2004.
HERCEPTIN A recent study showed that Herceptin, an antibody-based drug, helps women fight an aggressive form of early-stage breast cancer after surgery. The estimated sales for Herceptin in 2009 is about 4.2 billion francs. Roche's Breast Cancer Drug Gets More Positive Data, Reuters, April 28, 2005.
SORAFENIB Bayer and Onyx completed their US marketing application for sorafenib. Sorafenib blocks RAF kinase and VEGF that helps produce blood vessels which feed tumors. The market for sorafenib can be as high as $600 million after launching. 
Pfizer's SUTENT/SU11248 (sunitinib malate) Sutent pill is developed to treat gastrointestinal stromal tumors, a type of stomach cancer, and kidney cancer that has spread to other parts of the body and not been controlled by standard treatments. Sutent might have significant advantages over existing treatments. [1 For instance, new study shows Pfizer's SUTENT/SU11248 (sunitinib malate) extends overall survival in Novartis AG's Gleevec-resistant GIST.  About 5000-10,000 Americans were diagnosed with this cancer. 
Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases. Tyrosine kinases may be a molecular switch for cancer growth. Inhibition of these tyrosine kinases is believed to starve tumors of blood and nutrients needed for growth and simultaneously kill the cancer cells that make up tumors.
The FDA has granted Sutent fast-track status for review and Pfizer planned to seek FDA approval by August for the pill.
 Pfizer Submits Application for Sutent to FDA PR Wed Aug 10, 2005  New data show Pfizer's SUTENT/SU11248 (sunitinib malate) extends overall survival in Gleevec-resistant GIST Globandmail.com Aug 10, 2005  Pfizer seeks approval for cancer drug Reuters Aug 10 2005.
VACCINE Merck & Co is developing a vaccine called Gardasil which can protect women against four strains of the human papillomavirus (HPV). The papillomavirus are prime cause of cervical cancer and genital warts. The new vaccine may reach the market in 2006 to compete with GlaxoSmithKline's Cervarix. Merk is partnering with Sanofi-Aventis to seek first regulatory approvals for its vaccine in Europe. Currently, the cervical cancer victimizes about 470,000 women a year.A vaccine for cervical cancer found, Earthtimes.org, April 5, 2006
As the technologies improve, more new anticancer drugs with less side-effects are available in the market. This web-site collects and summarizes news and research findings about recently developed anti-cancer drug products.
New Anti-cancer Drugs